A CAUTIONARY TALE
The extraordinary rise and fall of Silicon Valley start-up Theranos is recounted in the unlikely page-turner Bad Blood.1 Only a few years ago, Theranos, and its iconic founder and supposed genius Elizabeth Holmes, were celebrated for their game-changing technology that was set to revolutionise diagnosis. With its promise of machines that could perform hundreds of blood tests on a single drop of blood, Theranos was valued at $9 bn, while Holmes was fêted with fame, honours, and awards. Her board was stacked with dignitaries such as elder statesmen Henry Kissinger and George Shultz. Such luminaries, along with investors like Rupert Murdoch, were all captivated by Holmes’s vision of painless, accurate, and cheap diagnostics that would save lives and make them billions.
The …
RCGP login
Members, please Login at RCGP to access the journal online.
Subscriber login
Enter your BJGP login information below.
Log in using your username and password
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
